Liraglutide High-quality spot inventory
TDS 29 Inquiries
204656-20-2
Pharmaceutical Grade
99%
china
JY
Aluminum foil bag
2026-02-28
Peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
Liraglutide is characterized as a white to almost white powder. It is freely soluble in aqueous base solutions (> 270 mg/mL), but its water solubility decreases below pH 7 and reaches its lowest level at pH 4-5 (approximately 0.05 mg/mL). Solubility increases marginally at pH 2.5 where it is very slightly soluble (≤ 0.8 mg/mL). Liraglutide is soluble in methanol (68 mg/mL) and very slightly soluble in ethanol (1.1 mg/mL). The isoelectric point of liraglutide is approximately 4.9. The pH of a 1 mg/mL aqueous solution of drug substance is approximately 9.3.
ChEBI: Liraglutide, a lipopeptide and polypeptide, is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Liraglutide functions as a glucagon-like peptide-1 receptor agonist and serves as a neuroprotective agent.
Liraglutide is GLP-1(1–37) modified at Ly: the -amino group is acylated with an (N-hexadecanoyl)glutam- -yl moiety that noncovalently but avidly binds tohuman serum albumin. (Also, Lys is conservatively replacedwith Arg.) These changes provide for a greatly extendedserum t12 of～10 to 15 hours after sc administration(0.6–1.8 mg), allowing for once-daily dosing.Liraglutide (Victoza, Novo Nordisk) is awaiting approvalby the FDA, EMEA, and the Koˉ roˉ -shoˉ (Japan).
Liraglutide peptide is a single, non-glycosylated polypeptide chain containing 31 amino acids, having a molecular mass of 3751 Dalton and a Molecular formula of C172H265N43O51.Certificates-
TDS
Basic Info-
Product Name:
Liraglutide
Other Name:Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide
CAS No.:204656-20-2
Molecular Formula:C172H265N43O51
InChIKeys:YSDQQAXHVYUZIW-VTFFJMQZNA-N
Molecular Weight:3751.202
Exact Mass:3748.95000
EC Number:810-818-7
Color/Form:White to Off-White
Categories:
Characteristics-
PSA:
1513.76000
XLogP3:6.12960
Melting Point:>182°C (dec.)
Critical Temperature & Pressure:Refrigerator
Research-
Class:
GLP-1 receptor agonist (acylated GLP-1 analog, 31-amino-acid peptide)
Status:FDA-approved (Victoza 2010, Saxenda 2014 for obesity)
Mechanism:A 31-amino-acid GLP-1 analog with a C16 fatty-acid chain (palmitoyl) attached to Lys26 via a gamma-glutamic acid spacer. This fatty-acid modification enables reversible binding to serum albumin, extending the half-life to ~13 hours and allowing once-daily dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
EC50 (GLP1R Ec50):~10 nM
Source:DrugBank: DB06655; Knudsen LB, et al. J Med Chem. 2000;43(9):1664-1669.DOI
Clinical Development:FDA:Victoza, Saxenda (approved 2010-01-25)
References-
ChEMBL:
CHEMBL1213363
DrugBank:KEGG DRUG:PubChem:Disclaimer:Liraglutide is FDA-approved as a prescription medicine (Victoza for T2DM, Saxenda for obesity). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
Carcinogenicity, Category 2
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H351 Suspected of causing cancer
H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptides
-
Location:
Room 5003, 5th Floor, Yau Lee Centre, 45 Yuen Yuen Road, Kwun Tong, Hong Kong
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2024
-
-
Inquiry History29 Inquiries
Country Product Purchase Quantity Date Posted 
India
China factory wholesale price supply high purity 99% cas 204656-20-2 Liraglutide injection
50 KG Sep 30, 2023
India
Liraglutide
1.00 KG Oct 8, 2024
India
Liraglutide-USP
150.00 G Oct 10, 2023 
United Kingdom
Liraglutide
20 MG Jul 8, 2026 
United States
Mic (Lipo C with B12), VIP, Ss31, glutathione and, Reta
50 MG Mar 4, 2026
India
liraglutide
1 KG Feb 25, 2026
United States
liraglutide
1 Jan 21, 2026
United States
liraglutide
1 MT Nov 22, 2025 
Reunion Island
Liraglutide
1 G Apr 14, 2025
United States
Liraglut
1 MT Feb 9, 2025 
Israel
Liraglutide
1 G Aug 26, 2024
India
Liraglutide
10 G Jun 26, 2024
India
Liraglutide
100 G Mar 4, 2024
United States
Semaglutide Liraglutide powder
10 G Feb 20, 2024
United States
MIC
2 MT May 20, 2026 
Canada
Liraglutide
1 KG Dec 8, 2025 
Brazil
Liraglutida
1 G Sep 29, 2025
United States
Liraglutide
1 KG Aug 13, 2025 
Sweden
liraglutide
1 KG Aug 4, 2025 
Pakistan
liraglutide injection
50 KG Jan 21, 2025 Post an enquiry for this product
